Scholarlink

Purpose of Review <p>This review compares three major North American osteoporosis guidelines: the American Association of Clinical Endocrinology (AACE), the Bone Health and Osteoporosis Foundation (BHOF), and the Osteoporosis Canada Clinical Practice Guideline (OCCPG). The paper evaluates differences in fracture risk assessment, diagnostic strategies, pharmacologic treatment recommendations, and follow-up approaches to determine how each guideline supports osteoporosis management and fracture prevention.</p> Recent Findings <p>Recent research supports anabolic therapies for patients at high fracture risk. Studies show these agents improve bone mineral density and reduce fracture rates, especially when followed by antiresorptive therapy. Emerging evidence also supports sequential treatment strategies and individualized risk assessment to optimize outcomes.</p> Summary <p>All three guidelines emphasize fracture prevention and early diagnosis but differ in risk thresholds, use of FRAX, and recommendations for newer therapies. Current evidence suggests anabolic-first approaches may improve outcomes in high-risk patients. Future research should focus on long-term safety, comparative effectiveness, and personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Similarities and Differences Between Three North American Treatment Guidelines for the Management of Osteoporosis

  • 期刊论文

  • 发表日期：

    2026年7月25日

查看全文
  • Gabriella Moraes Rae,
  • Kara Walisser,
  • Tanveer Towheed,
  • Jonathan D. Adachi

摘要

Purpose of Review

This review compares three major North American osteoporosis guidelines: the American Association of Clinical Endocrinology (AACE), the Bone Health and Osteoporosis Foundation (BHOF), and the Osteoporosis Canada Clinical Practice Guideline (OCCPG). The paper evaluates differences in fracture risk assessment, diagnostic strategies, pharmacologic treatment recommendations, and follow-up approaches to determine how each guideline supports osteoporosis management and fracture prevention.

Recent Findings

Recent research supports anabolic therapies for patients at high fracture risk. Studies show these agents improve bone mineral density and reduce fracture rates, especially when followed by antiresorptive therapy. Emerging evidence also supports sequential treatment strategies and individualized risk assessment to optimize outcomes.

Summary

All three guidelines emphasize fracture prevention and early diagnosis but differ in risk thresholds, use of FRAX, and recommendations for newer therapies. Current evidence suggests anabolic-first approaches may improve outcomes in high-risk patients. Future research should focus on long-term safety, comparative effectiveness, and personalized treatment strategies.